AstraZeneca’s Tagrisso plus Orpathys improves survival in MET-mutated lung cancer

A new combination therapy using AstraZeneca’s Tagrisso together with Hutchmed’s Orpathys has shown a survival benefit for patients with a specific form of non‑small cell lung cancer. The study focused on individuals whose tumors carry an EGFR mutation and a secondary MET alteration and who had progressed after earlier Tagrisso treatment.

In the trial, the dual regimen delayed disease progression and extended overall survival compared with standard chemotherapy. Patients receiving the combination lived longer on average, indicating a meaningful clinical advantage for this hard‑to‑treat subgroup.

AstraZeneca’s oncology executive highlighted the goal of delivering the first all‑oral, biomarker‑directed option for these patients worldwide. Tagrisso is already approved in major markets, while Orpathys is being commercialized by AstraZeneca following its acquisition of Hutchmed’s asset.